|Recent CHDI News|
|Written by Administrator|
|Friday, 27 February 2009 05:55|
CHDI Foundation, Inc. has appointed Cristina Sampaio, MD, PhD to the newly-created position of Chief Clinical Officer.
Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery platform. Galenea’s innovative platform will provide new insights into the disease mechanism.
Isis Pharmaceuticals, Inc. and CHDI Foundation, Inc. announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington’s disease (HD). This collaboration builds upon earlier successful alliances in which CHDI provided funding to support Isis’ early work in HD.
Audio-visual recordings of the scientific presentations from this year's CHDI conference in Palm Springs.
Induced pluripotent stem cells give investigators a new window into neurological disease.
A video postcard from CHDI's Sixth Annual Huntington's Disease Therapeutics Conference in Palm Springs.
CHDI Foundation, Inc. has appointed Keith Elliston, PhD, to the newly-created position of Vice President, Systems Biology.
CHDI Foundation, Inc. has entered into collaboration with the Friedrich Miescher Institute for Biomedical Research to develop an assay to quantify huntingtin, the protein that causes Huntington's disease.
Sangamo BioSciences, Inc. and CHDI Foundation, Inc. have announced a collaboration to develop a novel therapeutic for Huntington's disease based on Sangamo's proprietary zinc finger DNA binding protein technology.
CHDI Foundation, Inc. and Sage Bionetworks have announced a contiunation of their relationship through a project to apply advanced computaional modeling to the discovery and development of biomarkers and therapies for Huntington's disease.
CHDI Foundation, Inc. and Siena Biotech SpA have announced a collaboration to explore and validate molecular targets that could have therapeutics potential in Huntington's disease.
CHDI Foundation Inc., today announced the start of a planning and consultation process to combine the existing REGISTRY and COHORT longitudinal clinical observation studies of Huntington's disease (HD) into a worldwide initiative called Enroll-HD.
10/11/2010HD Nightly News from Prague
Highlights from the European Huntington's Disease Network's Plenary Meeting in Prague, Czech Republic
Charles Sabine has produced a video postcard from EHDN's Huntington's Disease Conference in Prague.
CHDI Foundation, Inc. (CHDI) and the National Institute of Neurological Disorders and Stroke (NINDS) have released a funding opportunity announcement (FOA) regarding an extramural program to preclinically validate therapeutic targets for Huntington's disease (HD). CHDI, a not-for-profit virtual biotech company that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of HD, will provide a $4.5 million gift to NINDS for "set aside" funds to support R01 research projects in addition to those financed within regular NINDS funding policies.
04/09/2010A Video Postcard from Palm Springs
Charles Sabine has produced a video postcard from CHDI's 5th Annual Huntington's Disease Therapeutics Conference.
Galapagos NV and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington's disease, announced today a new five-year collaboration focused on discovering novel drugs for Huntington's disease. Galapagos' service division BioFocus will perform the research and is eligible to receive US$41 million in research fees during the five-year collaboration.
Albany, NY - AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc., focused on the discovery of new therapeutic agents for the treatment of Huntington's disease.
The Wall Street Journal writes about Sage Bionetworks and its efforts to build an open-source collaborative effort to compile scientific databases in order to build powerful disease models, including Huntington's disease.
Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's Disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$37.5 million in research funding over the next three years.
Dotmatics Limited (Dotmatics), a leading provider of drug discovery informatics products and services, is pleased to announce they have been selected by CHDI Foundation, Inc. to provide scientific data management, data mining, and analysis solutions.
AMRI (NASDAQ: AMRI) and CHDI Foundation, Inc., a non-profit organization pursuing drugs that delay or slow Huntington’s disease (HD), announced today the commencement of a new collaboration agreement focused on the discovery of new therapeutic agents for the treatment of this disease.
Partnership will provide researchers with fully-authenticated supply of single-mutant cell culture models of Huntington's disease.
Galapagos NV and CHDI Foundation, Inc. announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million (€0.8 million) over 1.5 years.
07/15/2008New Partnership with Ingenuity
Ingenuity Systems and CHDI announce multi-year deal for a disease-specific knowledge platform.
Vertex establishes early-stage Huntington’s disease research collaboration with CHDI Foundation.
CHDI and the Coriell Institute for Medical Research have established the HD Community BioRepository for researchers investigating Huntington's disease.
May 1, 2008 – CHDI, Inc., recently renamed CHDI Foundation, Inc., and High Q Foundation, Inc. announced that CHDI has taken over primary responsibility for the types of Huntington’s disease research projects previously funded by High Q. CHDI will now be supporting the full gamut of Huntington’s disease research activities from basic discovery research through clinical development.